IKIngo Kilimann

Ingo Kilimann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ingo Kilimann has a total of 459 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MRI-derived brain aging trajectories across the Alzheimer’s continuum: links to cognition, pathology and lifestyle risk factors

    by Elizabeth Kuhn, Georgios Antonopoulos, Luca Kleineidam, Melina Stark, Sandra Roeske, Felix Hoffstaedter, Laura Waite, Oliver Peters, Julian Hellmann-Regen, Lukas Preis, et al.

    Background: The brain age gap (BAG), the difference between neuroimaging-predicted and chronological age, captures inter-individual variation in brain aging. Although sensitive to Alzheimer’s disease (AD) pathology, its longitudinal patterns across the clinical AD continuum and prognostic relevance remain unclear. Methods: 577 participants from the DELCODE cohort (>2,100 MRI scans) were analysed: healthy controls individuals (HC, N=202), and patients with subjective cognitive decline (SCD, N=248), mild cognitive impairment (N=93), and AD dementia (N=34). All underwent structural MRI, amyloid (Aβ 42/40 ) and phosphorylated tau181 assessment, and lifestyle-related dementia risk profiling (LIBRA). BAG was derived using brainageR. Associations with baseline cognition, cognitive decline, and clinical progression (up to eight years) were examined using mixed-effects and Cox models. Mediation analyses tested whether BAG accounted for LIBRA-cognition associations. Biomarker-related and clinical findings were replicated in ADNI (N=461). Findings: BAG showed excellent short-term reliability, increased stepwise across the clinical spectrum and was elevated in amyloid-positive SCD, but not in asymptomatic amyloid-positive HC. Longitudinal BAG increases were strongest in amyloid- and tau-positive participants (Aβ+T+). Higher BAG was associated with poorer baseline cognition and predicted cognitive decline, with strongest effects in Aβ+T+. All main findings replicated in ADNI. BAG was associated with LIBRA only in biomarker-negative participants and partly mediated associations with cognitive outcomes in DELCODE. Interpretation: BAG is a reliable non-invasive marker of structural brain health sensitive to AD pathology and to modifiable AD risk. Detectable divergence prior to objective cognitive impairment supports its relevance for early risk stratification and prevention-oriented research. Funding: Helmholtz AI Cooperation Unit (ZT-I-PF-5-163).

  • Open Access

    Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairment

    by Elizabeth Kuhn, Luca Kleineidam, Melina Stark, Oliver Peters, Julian Hellmann-Regen, Lukas Preis, Daria Gref, Josef Priller, Eike Jakob Spruth, Maria Gemenetzi, et al.

  • Open Access

    Pathways to resilience: relationships between cognitive reserve, psychological debt, and Alzheimer’s disease biomarkers

    by Hanna Boscheck, Maxie Luft, René Mauer, Selin Senguel, Ylenia D’ELia, Peter Dechent, Klaus Fliessbach, Wenzel Glanz, Stefan Hetzer, Daniel Janowitz, et al.

    Background: Potentially modifiable lifestyle and psychological factors may influence Alzheimer’s disease (AD)-related brain pathology and cognitive function, thereby influencing cognitive resilience in late life. Objective: This cross-sectional study investigated associations and pathways between lifestyle and psychological factors related to cognitive reserve and psychological debt, AD-related biomarkers, and cognitive function, as well as potential differences in these associations between AD risk groups. Methods: In total, 298 non-demented older adults (mean age = 69.5 years, 44% women) of the DELCODE study were included. Structural equation modeling was used to assess the associations between the constructs of cognitive reserve (education, occupational complexity, leisure activity participation) and psychological debt (depression and anxiety symptoms, neuroticism, sleep quality), manifest AD-related biomarkers (cerebrospinal fluid [CSF] amyloid-beta [Aβ] 42, splenial white matter hyperintensities [WMH], hippocampal volume), and latent cognitive function of increased AD risk (Preclinical Alzheimer’s Cognitive Composite [PACC]). In the structural equation model, biomarkers were transformed such that higher values indicated greater AD-related brain pathology and age was included as a covariate. Multigroup analyses assessed moderations by established AD risk modifiers, namely sex and apolipoprotein ε4 (APOE ε4) genotype. Results: In the total sample, higher cognitive reserve was associated with better cognitive function ( p = .005), independent of AD-related biomarkers. Higher cognitive reserve was associated with lower psychological debt ( p = .035); however, neither construct showed a significant association with the AD-related biomarkers ( p ≥ .177). AD-related biomarkers of CSF Aβ42 ( p = .021), splenial WMH ( p = .044), and hippocampal neurodegeneration ( p = .007) were each independently associated with lower cognitive function. Most associations were comparable between AD risk groups stratified by sex and APOE ε4 genotype. The relationships between cognitive reserve and psychological debt, and between CSF Aβ42 and splenial WMH were stronger in APOE ε4 non-carriers than in carriers (all p ≤ .020). Conclusions: Cognitive reserve emerges as a key resilience pathway, supporting late-life cognition independently of AD-related pathology, with largely consistent effects across AD risk groups. The role of psychological debt warrants longitudinal investigation, particularly in vulnerable older populations. Trial registration: German Clinical Trials Register: DRKS00007966, Registered: 4 May 2015.


  • Open Access

    Protocol of a dyadic, app-supported collaborative care intervention trial for informal caregivers of people living with dementia—the multi-center living@home study

    by Eva Gläser, Fabian Kleinke, Milena Armanowski, Maresa Buchholz, Andreas Fellgiebel, Marius Gerdes, Wolfgang Hoffmann, Bernhard Holle, Ingo Kilimann, Kerstin Köhler, et al.

    Background: Informal caregivers provide a large part of the care required by people living with dementia. With disease progression, the burden on caregivers typically increases. Dyadic interventions, addressing both the caregiver and the person living with dementia simultaneously, can help to stabilize home care settings. This study examines the effectiveness and cost-effectiveness of an app-assisted dementia care intervention. Methods: Living@home is a two-arm, randomized, controlled, multi-center interventional study designed to evaluate the effectiveness of a dyadic, app-based intervention on home care stability as well as the cost-effectiveness of this approach. The inclusion criteria are a formal diagnosis of dementia and living in their own home for the person with dementia, as well as access to a smartphone and internet for the informal caregiver. A total of 554 dyads will be recruited in five participating memory clinics and randomized (1:1 ratio, using block randomization) into either the intervention or the control group. The intervention group will receive personalized dementia care management for a period of 12 months. A mobile health app connecting caregivers with a Family Care Specialist offers informal caregivers access to memory clinics and Care Specialists at any time, monitoring of their health situation through real-time data collection, overview of care-related tasks, information and alerts tailored to the reported individual caregiver burden. The control group receives care-as-usual. Both groups will be assessed at baseline and after 12 months. The primary outcome is the caregiver’s perseverance time (Perseverance Time Scale), and crucial secondary supportive outcomes are neuropsychiatric symptoms in the person living with dementia (Neuropsychiatric Inventory), and the caregiver’s perceived burden (Zarit Burden Interview). Further secondary outcomes include the caregiver’s resilience and self-efficacy, the dyads’ physiological stress level (as measured by hair cortisol concentrations), health-related quality of life, caregiver depression and anxiety, dyads’ unmet needs, and cost-effectiveness. Intervention effects will be estimated by using multivariate regression analyses. Discussion: Evidence on the effectiveness and cost-effectiveness of the intervention created from this study can help to inform decision makers and support the transition of the intervention to standard care. Trial registration: ClinicalTrials.gov NCT07251088, Registered 25.11.2025

  • Open Access

    Patterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia

    by Lena Marth, Francisco J. Martinez-Murcia, Juan-Manuel Górriz-Sáez, Jannis Denecke, Michael Ewers, Catharina Prix, Anna Christina Stockbauer, Alexander Maximilian Bernhardt, Olivia Wagemann, Elisabeth Wlasich, et al.

    Behavioral and neuropsychiatric symptoms are common in frontotemporal dementia (FTD) and primary progressive aphasia (PPA). However, little is known about their patterns, time course, and association with brain atrophy. We, therefore, aimed to describe behavioral and neuropsychiatric phenotypes in patients with FTD and PPA, leveraging a hypothesis-free/data-driven approach. We included participants diagnosed with behavioral variant FTD (bvFTD) or PPA according to Rascovsky and Gorno-Tempini criteria from the German Center for Neurodegenerative Diseases Clinical Registry Study of Neurodegenerative Diseases-FTD prospective multicenter observational cohort study. Symptoms were assessed using the Neuropsychiatric Inventory-Questionnaire. Principal component analysis (PCA) was used to delineate symptom groups. Subsequently, frequency and severity across diagnostic groups were examined. We applied linear mixed-effects models to describe the longitudinal evolution of symptoms. Associations with MRI-assessed atrophy were investigated using linear regression models. A total of 314 patients (42.4% female, mean age 65.52 [SD 9.0] years) with bvFTD or PPA were included. MRI was available for 134 of 314 individuals. PCA revealed 4 natural symptom groups, labeled active behavioral, passive behavioral, affective, and psychotic phenotypes. Symptom groups were observed at comparable frequencies across diagnostic groups. Time from symptom onset (0.130 [0.044-0.217], p < 0.003), sex (1.376 [0.666-2.087], p < 0.001), and the interaction between the nonfluent variant of PPA and sex (-1.940 [-3.242 to -0.638], p = 0.004) showed a significant effect on the active behavioral phenotype, with symptom severity increasing over time and being most pronounced in men with bvFTD. Patients with bvFTD exhibited more severe passive behavioral symptoms compared with any other diagnostic group. For the affective phenotype, a significant interaction between time and sex (0.063 [0.010-0.117], p = 0.021) indicated a progressive increase in symptom severity in men over time. Furthermore, we found robust neuroanatomical correlations of passive behavioral symptoms with subcortical and bilateral frontal and cingulate cortical atrophy. Our findings demonstrate that behavioral and neuropsychiatric symptoms are prevalent in both bvFTD and PPA. Their severity depends on the disease duration, phenotypic group, and sex. This detailed understanding of symptomatology is crucial for optimizing patient care, diagnostic evaluations, and the design of clinical trials. Limitations comprise the lack of neuropathologic validation and the limited availability of MRI data.


  • Open Access

    Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairment

    by Elizabeth Kuhn, Luca Kleineidam, Melina Stark, Oliver Peters, Julian Hellmann-Regen, Lukas Preis, Daria Gref, Josef Priller, Eike Jakob Spruth, Maria Gemenetzi, et al.

    Background: Subjective cognitive decline (SCD) is common in older adults and may precede mild cognitive impairment (MCI). Whether longitudinal changes in self- or study partner (SP)-reported SCD improve early identification of individuals at risk for clinical progression, particularly along the Alzheimer’s disease (AD) biological continuum, remains unclear. Methods: We pooled data from two longitudinal observational cohorts (DELCODE and ADNI). Cognitively unimpaired (CU) participants were recruited through public advertisement or memory clinics and included if baseline amyloid status, ≥2 SCD assessments, and clinical follow-up were available. SCD was assessed using the Everyday Cognition questionnaire (self- and SP-report). Linear mixed-effects models examined longitudinal associations between SCD trajectories, baseline AD biomarkers, and progression to incident MCI. Multivariable Cox proportional hazards models tested whether one-year changes in SCD predicted subsequent progression. Findings: Among 770 participants (median age 69·9years [IQR 66·0–74·6]; 52·6% women; median follow-up 5·0years [4·0-7·0]), amyloid-positive individuals and those who progressed to MCI showed steeper longitudinal increases in both SCD reports. In amyloid-positive participants, only increases in SP-reported SCD differentiated progressors from non-progressors. One-year increases in SP-reported SCD predicted a higher risk of subsequent MCI compared with unchanged scores (hazard ratio 3·24 [95%CI 1·73-6·07]), with effects confined to amyloid-positive participants. Interpretation: Longitudinal increases in SP-reported cognitive difficulties, particularly over short intervals, are associated with near-term progression to MCI in amyloid-positive CU older adults. SP-based longitudinal monitoring may represent a low-burden approach to support earlier clinical surveillance in aging populations. Funding: German Center for Neurodegenerative Diseases, US National Institutes of Health.

  • Open Access

    Associations between digital speech features of automated cognitive tasks and trajectories of brain atrophy and cognitive decline in early Alzheimer's disease

    by Qingyue Li, Stefanie Koehler, Alexandra Koenig, Martin Dyrba, Elisa Mallik, Nicklas Linz, Josef Priller, Eike Spruth, Slawek Altenstein, Jens Wiltfang, et al.

    Background: Speech-based features extracted from telephone-based cognitive tasks show promise for detecting cognitive decline in prodromal and manifest dementia. Little is known about the cerebral underpinnings of these speech features. Objective: To examine associations between speech features, brain atrophy, and longitudinal cognitive decline in individuals at risk for Alzheimer's disease (AD). Methods: Healthy volunteers, individuals with subjective cognitive decline, and those with mild cognitive impairment completed phonebot-guided semantic verbal fluency (SVF) and 15-word verbal learning task (VLT). Speech features were automatically extracted, and a global cognitive score (SB-C score) was computed. We analyzed data from 161 participants for cognitive trajectories, 141 for cross-sectional brain atrophy, and 102 for longitudinal brain changes. Analyses were conducted using multiple linear regressions, mixed-effects models, and voxel-based morphometry. Results: The SB-C score was associated with bilateral hippocampal volumes, SVF features were primarily associated with left hemisphere regions, including the inferior frontal, parahippocampal, and superior/middle temporal gyri ( p uncorr < 0.001). SB-C score, SVF correct counts, and VLT delayed recall were associated with atrophy rates in the hippocampal/parahippocampal gyrus and left middle/inferior temporal gyri ( p FDR < 0.05). These features were also associated with cognitive decline assessed via Preclinical Alzheimer's Cognitive Composite 5, SVF, and Wordlist learning delayed recall ( p FDR < 0.01). Word frequency and temporal cluster switches showed varying associations with cognitive trajectories. Other features did not show robust associations. Conclusions: In this study, we highlight the potential of digital speech features for identifying brain atrophy and cognitive decline over time in at-risk AD populations.


  • Open Access

    Speech-based digital cognitive assessments for detection of mild cognitive impairment: Validation against paper-based neurocognitive assessment scores

    by Zampeta-Sofia Alexopoulou, Stefanie Köhler, Elisa Mallick, Johannes Tröger, Nicklas Linz, Eike Spruth, Klaus Fliessbach, Claudia Bartels, Ayda Rostamzadeh, Wenzel Glanz, et al.

    Background: Cognitive decline in Alzheimer's disease (AD) often includes speech impairments, where subtle changes may precede clinical dementia onset. As clinical trials focus on early identification of patients for disease-modifying treatments, digital speech-based assessments for scalable screening have become crucial. Objective: This study aimed to validate a remote, speech-based digital cognitive assessment for mild cognitive impairment (MCI) detection through the comparison with gold-standard paper-based neurocognitive assessments. Methods: Within the PROSPECT-AD project, speech and clinical data were obtained from the German DELCODE and DESCRIBE cohorts, including 21 healthy controls (HC), 110 participants with subjective cognitive decline (SCD), and 59 with MCI. Spearman rank and partial correlations were computed between speech-based scores and clinical measures. Kruskal-Wallis tests assessed group differences. We trained machine learning models to classify diagnostic groups comparing classification accuracies between gold-standard assessment scores and a speech-based digital cognitive assessment composite score (SB-C). Results: Global cognition, as measured by SB-C, significantly differed between diagnostic groups ( H (2) = 30.93, p < 0.001). Speech-based scores were significantly correlated with global anchor scores (MMSE, CDR, PACC5). Speech-based composites for memory, executive function and processing speed were also correlated with respective domain-specific paper-based assessments. In logistic regression classification, the model combining SB-C and neuropsychological tests at baseline achieved a high discriminatory power in differentiating HC/SCD from MCI patients (Area Under the Curve = 0.86). Conclusions: Our findings support speech-based cognitive assessments as a promising avenue towards remote MCI screening, with implications for scalable screening in clinical trials and healthcare.


  • Open Access

    A computational ontology framework for the synthesis of multi-level pathology reports from brain MRI scans

    by Devesh Singh, Alice Grazia, Achim Reiz, Andreas Hermann, Slawek Altenstein, Lukas Beichert, Alexander Bernhardt, Katharina Buerger, Michaela Butryn, Peter Dechent, et al.

    Background: Convolutional neural network (CNN) based volumetry of MRI data can help differentiate Alzheimer's disease (AD) and the behavioral variant of frontotemporal dementia (bvFTD) as causes of cognitive decline and dementia. However, existing CNN-based MRI volumetry tools lack a structured hierarchical representation of brain anatomy, which would allow for aggregating regional pathological information and automated computational inference. Objective: Develop a computational ontology pipeline for quantifying hierarchical pathological abnormalities and visualize summary charts for brain atrophy findings, aiding differential diagnosis. Methods: Using FastSurfer, we segmented brain regions and measured volume and cortical thickness from MRI scans pooled across multiple cohorts (N = 3433; ADNI, AIBL, DELCODE, DESCRIBE, EDSD, and NIFD), including healthy controls, prodromal and clinical AD cases, and bvFTD cases. Employing the Web Ontology Language (OWL), we built a semantic model encoding hierarchical anatomical information. Additionally, we created summary visualizations based on sunburst plots for visual inspection of the information stored in the ontology. Results: Our computational framework dynamically estimated and aggregated regional pathological deviations across different levels of neuroanatomy abstraction. The disease similarity index derived from the volumetric and cortical thickness deviations achieved an AUC of 0.88 for separating AD and bvFTD, which was also reflected by distinct atrophy profile visualizations. Conclusions: The proposed automated pipeline facilitates visual comparison of atrophy profiles across various disease types and stages. It provides a generalizable computational framework for summarizing pathologic findings, potentially enhancing the physicians’ ability to evaluate brain pathologies robustly and interpretably.


  • Open Access

    Identifying Unmet Needs of Informal Dementia Caregivers in Clinical Practice: User-Centered Development of a Digital Assessment Tool

    by Olga A Biernetzky, Jochen René Thyrian, Melanie Boekholt, Matthias Berndt, Wolfgang Hoffmann, Stefan J Teipel, Ingo Kilimann

    Background: Despite the increasing interventions to support family caregivers of people with dementia, service planning and delivery is still not effective. Objective: Our study aimed to develop a digitally-supported needs assessment tool for family caregivers of people with dementia that is feasible, time-efficient, understood by users, and can be self-completed in the primary care setting. Methods: The development of the unmet needs assessment tool was part of a cluster-randomized controlled trial examining the effectiveness of a digitally supported care management programme to reduce unmet needs of family caregivers of people with dementia (GAIN [Gesund Angehörige Pflegen]) and was conducted in 3 phases. Using an iterative participatory approach with informal caregivers, health care professionals including general practitioners, neurologists, psychologists, psychiatrists, nurses, and Alzheimer Society representatives, we developed a digital self-completion unmet needs assessment tool focusing on informal caregivers’ biopsychosocial health und quality of life in connection to their caregiver responsibilities. Data were collected through group discussions, written feedback, protocols, think-aloud protocols, and interviews, and analyzed thematically. Results: Data from 27 caregivers, including caregivers of people with dementia (n=18), health care professionals (n=7), and Alzheimer Society representatives (n=2) were collected. Thematic analysis identified 2 main themes: content of the assessment tool and usability and handling of the digital tablet-based assessment tool. The feedback provided by the stakeholders led to new aspects and changes to make the tool comprehensive, easy to read, and easy to handle. The overall mean completion time was reduced from the initial 37 minutes to 18 minutes, which renders the assessment tool fit to be self-completed in waiting rooms of primary care practices or other settings. Conclusions: The input of the 3 stakeholder groups has supported the development of the assessment tool ensuring that all aspects considered important were covered and understood and the completion of the assessment procedure was time-efficient and practically feasible. Further validation of the assessment tool will be performed with the data generated as part of the GAIN trial.